Elizabeth Ren Zhang-Velten, MD, PhD

home / authors / elizabeth-ren-zhang-velten-md-phd

Articles

Oncologists Reflect on Pandemic's Lasting Impact on Cancer Care

Oncologists Reflect on Pandemic's Lasting Impact on Cancer Care

Aditya Bardia, MD, MPH;Ritu Salani, MD;Scarlett Lin Gomez, PhD;Marwan G. Fakih, MD;Elizabeth Ren Zhang-Velten, MD, PhD;Frances Chow, MD;James B. Yu, MD, MHS, FASTRO
March 10th 2025

Hear from leading cancer experts about the lasting impact the COVID-19 pandemic has left on clinical practice.

The Evolution and Innovation in Care for Brain Metastases

The Evolution and Innovation in Care for Brain Metastases

Elizabeth Ren Zhang-Velten, MD, PhD
February 26th 2025

Care for brain metastases is constantly evolving, and now, physicians can use targeted systemic therapies as well as more focal radiation to treat them.

Latest Updated Articles

Treosulfan plus fludarabine is now approved by the FDA as an injection for allo-HSCT conditioning for patients with AML or MDS.
Published: January 24th 2025 | Updated: February 6th 2025
FDA Approves Treosulfan Combo Injection for HSCT Conditioning in AML/MDS
Non–clear Cell RCC: First-Line Treatment Options and Guideline Updates
Published: September 13th 2024 | Updated: November 25th 2024
Non–clear Cell RCC: First-Line Treatment Options and Guideline Updates
NSABP B-42 trial results show that the assay was predictive of extended letrozole therapy response, identifying a patient subset with improved outcomes.
Published: August 9th 2024 | Updated: August 14th 2024
Gene Assay May Predict Extended Letrozole Benefits in Breast Cancer Subsets
OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer
Published: June 2nd 2024 | Updated: June 3rd 2024
OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer
Data from the CheckMate-67T trial support the biologics license application for subcutaneous nivolumab in multiple solid tumors.
Published: May 6th 2024 | Updated: May 21st 2024
FDA Accepts BLA for Subcutaneous Nivolumab in Solid Tumor Indications
Leukocytoclastic Vasculitis Induced by Immune Checkpoint Inhibition in a Patient With Advanced Renal Cell Carcinoma
Published: May 11th 2022 | Updated: April 20th 2025
Leukocytoclastic Vasculitis Induced by Immune Checkpoint Inhibition in a Patient With Advanced Renal Cell Carcinoma